Myostatin inhibitors are a class of investigational drugs that block myostatin, a protein that acts as a natural 'brake' on muscle growth. By disabling this brake, these agents can induce significant muscle hypertrophy, making them a powerful theoretical tool against age-related muscle loss (sarcopenia). However, human trials for muscle-wasting diseases have shown mixed results, often increasing muscle mass without a corresponding improvement in functional strength, and have been associated with safety concerns.
Verdict
Highly experimental with major safety concerns; not ready for healthspan applications.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
Very High
EVIDENCE GRADE
C
MONTHLY COST
$500 - $2000
Protocol
- No established protocol exists for healthspan; all use is investigational.
- Clinical trials for disease have used subcutaneous or intravenous injections every 2-4 weeks.
Flags
- None are approved for human use; typically sourced as unregulated research chemicals.
- Past clinical trials were halted due to adverse events like minor bleeding and vascular issues.
- Long-term effects on the heart, tendons, and systemic metabolism are unknown.
- Observed increases in muscle mass may not translate to proportional gains in functional strength.